{"id":5240,"date":"2025-07-11T23:02:29","date_gmt":"2025-07-11T23:02:29","guid":{"rendered":"https:\/\/mailitics.com\/index.php\/2025\/07\/11\/biotech-news-capricor-fda-merck-moderna-verona-cirm-stem-cell-duchenne-the-readout\/"},"modified":"2025-07-11T23:02:29","modified_gmt":"2025-07-11T23:02:29","slug":"biotech-news-capricor-fda-merck-moderna-verona-cirm-stem-cell-duchenne-the-readout","status":"publish","type":"post","link":"https:\/\/mailitics.com\/index.php\/2025\/07\/11\/biotech-news-capricor-fda-merck-moderna-verona-cirm-stem-cell-duchenne-the-readout\/","title":{"rendered":"STAT+: Questions about the FDA\u2019s \u2018radical transparency\u2019 efforts"},"content":{"rendered":"

STAT+: Questions about the FDA\u2019s \u2018radical transparency\u2019 efforts
\n \t

\n
<\/BR>
\n
\n \t

\n
<\/BR><\/p>\n

\n

Want to stay on top of the science and politics driving biotech today?\u00a0Sign up<\/a>\u00a0to get our biotech newsletter in your inbox.<\/em><\/p>\n

Happy Friday. Today, we talk about the stem cell fire sale at CIRM, and about\u00a0the FDA\u2019s move to release\u00a0a limited batch of complete response letters.<\/p>\n

FDA rejects Capricor\u2019s cell therapy for Duchenne muscular dystrophy<\/h2>\n

From my colleague Adam Feuerstein:<\/em> The Food and Drug Administration rejected a marketing application<\/a> from Capricor Therapeutics seeking clearance for a cell therapy to treat Duchenne muscular dystrophy, the company said this morning.<\/p>\n

Continue to STAT+ to read the full story\u2026<\/a><\/p>\n<\/div>\n

\t

\n
<\/BR>
\n Meghana Keshavan
\n \t

\n
<\/BR>
\nGo to statnews<\/a>
\n \t

\n
<\/BR><\/p>\n","protected":false},"excerpt":{"rendered":"

STAT+: Questions about the FDA\u2019s \u2018radical transparency\u2019 efforts Want to stay on top of the science and politics driving biotech today?\u00a0Sign up\u00a0to get our biotech newsletter in your inbox. Happy Friday. Today, we talk about the stem cell fire sale at CIRM, and about\u00a0the FDA\u2019s move to release\u00a0a limited batch of complete response letters. FDA […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2194,2154,58,2208,2209,2176,858,2207],"tags":[2150],"class_list":["post-5240","post","type-post","status-publish","format-standard","hentry","category-biotech","category-biotechnology","category-business","category-drug-development","category-drug-prices","category-pharma","category-research","category-the-readout","tag-statnews"],"_links":{"self":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts\/5240"}],"collection":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/comments?post=5240"}],"version-history":[{"count":0,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts\/5240\/revisions"}],"wp:attachment":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/media?parent=5240"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/categories?post=5240"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/tags?post=5240"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}